On 18 March, the FluiDx-AD project released its inaugural external newsletter. Funded by the European Union’s Horizon Europe programme with a budget of EUR 7,699,219.38 for three and a half years, it aims to improve the early diagnosis and management of Alzheimer’s disease (AD). Current diagnostic tools, such as brain imaging and cerebrospinal fluid tests, are partially invasive, costly and often only used in already advanced disease stages. FluiDx-AD addresses these limitations by developing minimally invasive, cost-effective in vitro diagnostic (IVD) tests using saliva and blood samples. This and the future newsletter issues will introduce you to our early-career researchers and investigators, project achievements as well as our activities.
